Anker G B, Lønning P E, Aakvaag A, Lien E A
Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Scand J Clin Lab Invest. 1998 Apr;58(2):103-7. doi: 10.1080/00365519850186670.
Thyroid function was evaluation in 26 postmenopausal women with breast cancer before and at various time intervals during treatment with tamoxifen. Tamoxifen treatment suppressed plasma levels of FT3 and FT4 (p < 0.005 for both) and elevated plasma concentrations of TBG (p < 0.005 and TG (p < 0.025). In general, these changes became significant after 6 months of treatment. Plasma TSH increased significantly after 1 y of treatment (p < 0.025). A fall in FT4 and FT3 combined with increase in TSH suggests a reduced bioavailability of T4 and T3 during tamoxifen treatment. The increase in TG may reflect a reduced synthesis or liberation of T4 resulting in a reduced plasma level of FT4. Our findings suggest that tamoxifen influences the thyroid hormone levels, not only by modulating plasma TBG, but also by interfering with hormone synthesis or secretion in the thyroid gland.
对26名绝经后乳腺癌女性在服用他莫昔芬治疗前及治疗期间的不同时间间隔进行甲状腺功能评估。他莫昔芬治疗可抑制血浆FT3和FT4水平（两者均为p < 0.005），并升高血浆TBG浓度（p < 0.005）和TG浓度（p < 0.025）。一般来说，这些变化在治疗6个月后变得显著。治疗1年后血浆TSH显著升高（p < 0.025）。FT4和FT3下降以及TSH升高表明在他莫昔芬治疗期间T4和T3的生物利用度降低。TG升高可能反映T4合成或释放减少，导致血浆FT4水平降低。我们的研究结果表明，他莫昔芬影响甲状腺激素水平，不仅通过调节血浆TBG，还通过干扰甲状腺激素的合成或分泌。
